Article
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast cancer research and treatment - 1 Jul 2014
Gronwald Jacek, Robidoux Andre, Kim-Sing Charmaine, Tung Nadine, Lynch Henry T, Foulkes William D, Manoukian Siranoush, Ainsworth Peter, Neuhausen Susan L, Demsky Rochelle, Eisen Andrea, Singer Christian F, Saal Howard, Senter Leigha, Eng Charis, Weitzel Jeffrey, Moller Pal, Gilchrist Dawna M, Olopade Olufunmilayo, Ginsburg Ophira, Sun Ping, Huzarski Tomasz, Lubinski Jan, Narod Steven A
Abstract excerpt
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.